Who are Pacira BioSciences, Inc.'s core surgical customers and outpatient centers?
Pacira BioSciences, Inc. targets surgical teams and outpatient surgery centers focused on opioid-sparing pain control. Their market matters because payers and hospitals pushed multimodal analgesia in 2025, driving adoption of long-acting local analgesics and shifting procedures to ambulatory settings.
High-volume orthopedic, colorectal, and bariatric surgeons drive repeat demand; bundled payments and outpatient migration raised product uptake in 2025. See product positioning: Pacira Marketing Mix 4P
Who Makes Up Pacira's Core Customer Base?
Pacira BioSciences, Inc. primarily serves institutional healthcare providers – Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs) – with surgeons and anesthesiologists as clinical gatekeepers; these institutions buy at scale via formularies and contracts, driving product adoption in 2025/2026.
Main Customer Group
ASCs and HOPDs are the main customer group because they now perform more outpatient arthroplasty and soft-tissue procedures; in 2025 ASCs accounted for roughly 50% of EXPAREL volume, shifting revenue mix toward outpatient channels.
Secondary Customer Groups
Secondary groups include hospitals and health systems, chronic pain clinics, and specialty practices (orthopedics, plastics, rheumatology); these buyers use ZILRETTA and Exparel for osteoarthritis and postoperative pain management.
Customer Type and Market Role
Pacira customers are mainly institutional (B2B) healthcare providers with clinical users (surgeons, anesthesiologists) as influencers; Pacira secures formulary placement with pharmacy and therapeutics committees and IDN purchasing teams.
Most Commercially Important Segment
The most commercially important segment in 2025/2026 is large ASC chains and Integrated Delivery Networks (IDNs) where corporate contracts drive volume and where EXPAREL adoption – supported by data on cost-effectiveness and opioid-sparing – is concentrated.
Pacira targets decision makers such as pharmacy directors, P&T committees, ASC administrators, and IDN contracting teams, while anesthesiologists and surgeons influence clinical adoption and ordering patterns.
Who the Company's Core Customers Are
Core customers are institutional purchasers at ASCs, HOPDs, and large health systems; surgeons and anesthesiologists drive clinical use, while administrators and P&T committees control purchasing and formulary access.
- ASCs and HOPDs as the main customer group
- Chronic pain clinics and specialty practices as a secondary segment
- Mainly B2B – institutions with clinician influencers
- Large ASC chains/IDNs are the most commercially important segment
For additional context on corporate structure and ownership relevant to how Pacira markets to healthcare providers and systems, see Ownership of Pacira Company
Pacira SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drives Pacira's Customers to Buy?
Pacira BioSciences, Inc. customers need effective postsurgical pain control that reduces opioid use, shortens recovery, and avoids opioid-related adverse events; hospitals and clinicians buy Pacira products to meet quality, reimbursement, and patient-safety goals driven by 2025 – 2026 policy and payer shifts.
Manage intense postoperative pain without opioids
Pacira helps control severe postoperative pain over the critical first 72 hours after surgery, reducing reliance on systemic opioids and lowering risks like respiratory depression and nausea.
Reimbursement, cost-effectiveness, and workflow fit
Hospitals and ambulatory surgery centers choose Pacira for reimbursable non-opioid options, predictable dosing, and shorter LOS; the NOPAIN Act (2026) expanded Medicare payment for non-opioid outpatient treatments, improving economics.
Patient preference for opioid-sparing care
Patients and families increasingly prefer non-opioid strategies; Pacira products appeal to those aiming to avoid narcotics, supporting satisfaction and perceived safety.
Clinical efficacy and reduced adverse events
Clinicians value EXPAREL's long-acting local analgesia and iovera's immediate non-pharmacologic nerve block for lowering opioid-related complications and enabling earlier mobilization.
Repeat use driven by outcomes and protocols
Consistent reductions in opioid consumption and shorter observation times support protocol adoption, formulary inclusion, and recurring procurement by surgical departments and pain clinics.
Clear value: opioid-sparing, reimbursable therapy
Pacira wins when hospitals and anesthesiology teams prioritize opioid-sparing care that is evidence-based, reimbursed, and demonstrably reduces discharge delays and adverse-event costs.
Key buyer groups include hospitals and health systems, ambulatory surgery centers, anesthesiologists and surgeons, and pain management clinics evaluating Exparel target audience and iovera use for perioperative protocols.
Who Uses Pacira Products and Why They Buy
Decision makers – chiefs of surgery, anesthesiology directors, pharmacy and therapeutics committees, and ASC operators – buy Pacira products to reduce opioid exposure, shorten length of stay, and capture Medicare reimbursement under newer policies.
- Reduce postoperative opioid use and opioid-related complications
- Reimbursement and demonstrable cost-effectiveness after NOPAIN Act changes
- Patient preference for opioid-sparing, rapid-acting options
- Proven 72-hour pain coverage and integration into perioperative pathways
What These Customers Need and Why They Buy: Customers choose Pacira offerings to provide multi-day local analgesia (EXPAREL) and immediate non – pharmacologic nerve block (iovera), lowering opioid use and enabling faster recovery; Medicare reimbursement changes in 2026 materially improved the economic case for adoption – hospitals purchasing Exparel report lower opioid-related adverse events and shorter PACU stays.
For deeper background on company evolution and market positioning see History of Pacira Company
Pacira PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Where Does Pacira Find the Most Demand?
Pacira BioSciences, Inc. finds its target market concentrated in the United States, which accounted for over 95% of 2025 revenue; demand is strongest in states with large Medicare-age populations and active private-payer markets such as Florida, Texas, California, and Arizona, concentrated in surgical hubs and specialized orthopedic clinics.
Main U.S. Surgical and Outpatient Market
Pacira target market centers on U.S. hospitals and health systems, ambulatory surgery centers, and pain management clinics where Exparel target audience includes anesthesiologists and surgeons seeking non-opioid postoperative analgesia.
Secondary Markets and High-Growth Verticals
Secondary demand appears in podiatry and pediatric surgical segments after label expansions, plus growing uptake in rural and community hospitals adopting ERAS protocols to cut length of stay and opioid use.
Where Pacira Is Strongest
Pacira customers are concentrated in outpatient surgical infrastructure and orthopedic centers where Exparel drives perioperative analgesia spend; the company shows strongest brand presence in high-volume surgical states and among pharmacists and P&T committees evaluating cost-effectiveness.
Fastest-Growing Demand Areas (2025 – 2026)
Demand is growing fastest in ambulatory surgery centers and community hospitals adopting non-opioid strategies, and in regions expanding ERAS protocols where insurers and payers increasingly evaluate Exparel for postoperative pain control.
Pacira's revenue mix remains heavily U.S.-tilted; regional hospital markets targeted by Pacira sales include Sun Belt states with aging populations and high surgical volumes, while international expansion in Europe and Asia remains strategic but limited in 2025.
Geographic Revenue and Customer Mix
In 2025, U.S. revenue exceeded 95% of total sales; customers span tertiary hospitals, ambulatory surgery centers, and specialized clinics, with payer mix skewed to Medicare and commercial insurance.
Market Concentration
Pacira depends on a concentrated U.S. market rather than broad global sales; a handful of high-volume states drive a disproportionate share of Exparel purchases and formulary decisions.
Differences Across Markets
Urban academic centers prioritize multimodal analgesia and research adoption, while community hospitals focus on cost-effectiveness and ERAS metrics; ambulatory centers weigh throughput and same-day discharge benefits.
Local Fit and Market Access
Success hinges on formulary placement, pharmacy and therapeutics committee approvals, and regional sales access to anesthesiologists and surgeons who decide to purchase Exparel for postoperative pain management.
Growth Exposure
Exposure is tilted to mature U.S. surgical markets but benefits from faster-growing ambulatory surgery centers and community hospitals expanding ERAS, which present higher marginal adoption rates in 2025 – 2026.
Strongest Market Opportunity
The clearest opportunity is expanding Exparel adoption in ambulatory surgery centers and community hospitals in Sun Belt states – where patient profiles, payer mix, and ERAS uptake align to boost demand.
Where Pacira Finds Its Target Market
Pacira target market is heavily U.S.-centric, driven by hospitals and ambulatory centers seeking non-opioid analgesia; primary customers are anesthesiologists and surgeons managing postoperative pain.
- U.S. hospitals and health systems in high-surgery states
- Podiatry, pediatric surgery, and ambulatory surgery centers as secondary demand areas
- Strongest in outpatient surgical infrastructure and orthopedic clinics
- Growth concentrated in ambulatory surgery centers and community hospitals adopting ERAS
For context on competitive positioning and market dynamics, see Competitive Landscape of Pacira Company
Pacira Business Model Canvas
- Complete Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
How Does Pacira Grow and Keep Its Customer Base?
Pacira BioSciences, Inc. grows its customer base by securing new FDA indications and driving clinical evidence for EXPAREL and adjunct products, while strengthening retention through clinician training, bundled product offerings, and real-world cost-effectiveness data that lower churn among hospital systems by demonstrating reduced episode-of-care costs.
How Pacira Expands Its Customer Base
Pacira expands reach by gaining new indications (eg, lower extremity nerve blocks, expanded pediatric use) that increase TAM by millions of annual procedures, pursuing hospital formularies, and targeting ambulatory surgery centers and regional hospital markets with data showing lower total care costs. See the company outlook for strategic context: Growth Strategy and Outlook of Pacira Company
Customer Retention Drivers
Pacira retains customers via Innovation and Training Centers that teach EXPAREL technique to anesthesiologists and surgeons, building high switching costs; bundled offerings with iovera and ZILRETTA deepen institutional adoption across hospitals and ambulatory surgery centers.
Loyalty, Repeat Demand, and Customer Depth
Repeat demand is driven by perioperative protocol adoption in orthopedic groups and pain management clinics; customers renew use as real-world evidence shows fewer opioid prescriptions and faster throughput, supporting formulary retention among payers and pharmacy & therapeutics committees.
Strongest Customer-Base Growth Lever
The primary growth lever is clinical evidence plus indication expansion: by 2025/2026, regulatory wins and published real-world cost-offset data have materially increased hospital and ambulatory surgery center adoption of EXPAREL, driving higher penetration among anesthesiologists and surgeons.
Pacira Marketing Mix
- Covers Marketing Mix Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- How Does Pacira Company Compete in Its Market?
- What Is the Growth Strategy and Outlook of Pacira Company?
- How Did Pacira Company Start and Evolve Over Time?
- What Do the Mission, Vision, and Core Values of Pacira Company Reveal?
- Who Owns Pacira Company and Who Controls It?
- How Does Pacira Company Reach Customers and Drive Sales?
- How Does Pacira Company Work and Make Money?
Frequently Asked Questions
Pacira's main customers are institutional healthcare providers, especially Ambulatory Surgery Centers and Hospital Outpatient Departments. These buyers purchase at scale through formularies and contracts, while surgeons and anesthesiologists act as the main clinical influencers. Large ASC chains and Integrated Delivery Networks are the most commercially important segment.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.